Alpha Paradigm Partners’s Heron Therapeutics HRTX Stock Holding History

Alpha Paradigm Partners’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-173,473	Closed	-$1.58M	–	610
2021 Q4	$1.58M	Buy	173,473 +109,952	+173%	+$1.12M	0.64%	24
2021 Q3	$679K	Buy	63,521 +23,034	+57%	+$280K	0.27%	123
2021 Q2	$628K	Buy	+40,487	New	+$644K	0.24%	143
2021 Q1	–	Sell	-18,645	Closed	-$395K	–	562
2020 Q4	$395K	Buy	+18,645	New	+$324K	0.14%	183

Other funds holding HRTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Alpha Paradigm Partners's HRTX Position: Q1 2022 in Review

Alpha Paradigm Partners sold out of Heron Therapeutics (HRTX) in Q1 2022, closing a stake of 173,473 shares — an estimated $1.58M sold.

Alpha Paradigm Partners first reported a position in HRTX in Q4 2020 and held it in 4 quarters. The position peaked at $1.58M in Q4 2021. 186 funds tracked by Wall St. Rank hold HRTX as of Q1 2022.

Alpha Paradigm Partners reported no remaining Heron Therapeutics position as of Q1 2022 after selling out during the quarter.
Alpha Paradigm Partners sold 173,473 Heron Therapeutics shares in Q1 2022, an estimated $1.58M.
Alpha Paradigm Partners first reported a position in Heron Therapeutics in Q4 2020 and held it in 4 quarters.
Alpha Paradigm Partners's Heron Therapeutics position peaked at $1.58M in Q4 2021.
186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2022.

Based on Alpha Paradigm Partners's 13F filing for Q1 2022, filed 16 May 2022.